Fig 1: Targeting TGF-βRI ALK5 kinase by A83-01 inhibited TGF-β-induced Twist and Wnt3. The cells were incubated with A83-01 for 16 h and then treated with TGF-β at indicated time. A total protein levels of pSmad3 and Twist were determined by Western blot analysis. B Localization of pSmad3 (a, c, e Texas red) and Twist (g, i, k FITC green) protein was determined by Immunofluorescence analysis (IF) as described in the “Methods” section. White arrows indicate cytoplasmic expression and yellow arrows indicate nuclear expression. b, d, f Merged pSmad3-Texas red and cell nuclei labeled with DAPI blue, and h, j, l merged Twist-FITC (green) and cell nuclei labeled with propidium iodide (PI) (red). C Localization of β-catenin was determined by IF. a–c show cell nuclei labeled with PI (red), and d–f, show β-catenin labeled with FITC (green). g–i Merged β-catenin-FITC and cell nuclei labeled with PI. White arrows indicate cytoplasmic expression and yellow arrows indicate nuclear expression. D Total protein level of Wnt3 was determined by Western blot analysis
Fig 2: TGF-β induces Twist transcriptionally upregulating Wnt3 and leads to activate Wnt/β-catenin pathway. a top E-box located in promoter of Wnt3 where Twist binding allowed; bottom Cells were treated with or without TGF-β and ChiP-qPCR assay was performed as described in “Methods” section. The bars indicate the fold enrichment of Twist binding to the promoter of Wnt3 in the indicated cells with or without TGF-β induction and compared to Mock cells (immunoprecipitated with IgG). b The cells were treated with shRNA Twist or negative sequence for 48 h. RT-qPCR was conducted with Twist primer and the bars in left indicated relative expression of Twist (mean ± SD from three determinations) adjusted with 18S, *p < 0.05 compared to untreated cells. In the right, Western blot was performed with antibodies specific for Twist and Wnt3. The β-actin was used for loading control. c The cells were treated with Twist shRNA or negative control sequence and then induced with or without TGF-β. The nuclear or cytoplasm expressions of β-catenin were determined by Western blot analysis. The α-Tubulin and H3 were used for loading control of cytoplasm and nuclear protein respectively. d The bar graph indicates the regulation of Wnt/β-catenin pathway signaling in SKBR3 wild type (blue bars), wild-type cells treated with TGF-β (red bars) and shRNA Twist knocking down cells (black and green bars) treated with TGF-β compared to untreated SKBR3 (blue bars) analyzed by specific Wnt/β-catenin mRNA array. The relative level of each indicated gene was adjusted with GAPDH and each bar indicates mean fold change and SD from four determinations
Fig 3: TGF-β upregulates Wnt3 and activates β-catenin pathway. a Bar graph of regulated Wnt/β-catenin pathway signaling in SKBR3 treated with TGF-β (dark bars) compared to untreated SKBR3 (open bars) analyzed by specific Wnt/β-catenin mRNA array as described in “Methods” section. The relative level of each indicated gene was adjusted with GAPDH and each bar indicates mean fold change and SD from four determinations, *p < 0.05 and **p < 0.01 compared to untreated cells. b SKBR3 cells were treated with TGF-β for 24 h and RNA was extracted. RT-qPCR was performed with the primers for Wnt ligands (left) and FZD receptors (right). The bars indicate relative expression of the indicated genes adjusted to 18S (mean ± SD from three determinations), ^p < 0.05 compared to the untreated SKBR3 cells, *p < 0.05 compared to untreated cells. c The cells were treated with TGF-β ± anti-TGF-β antibody for 24 h or TGF-β ± anti-Wnt3 antibody. The medium was collected and the attached cells were used for extraction of RNA or protein. c (left) The Wnt3 level in the conditioned medium was measured by ELISA and calculated as per one million cells/ml as described in “Methods” section. The bars indicate mean from two experiments (each experiment had duplicated measurements) plus standard deviation, *p < 0.05 compared to untreated cells, ^p < 0.05 compared to untreated SKBR3 cells (control). c (middle) RT-qPCR was performed with Wnt3 and Twist primers. The bars indicate relative expression of Wnt3 or Twist (mean ± SD from three determinations) and adjusted for 18S. The dark and open bars indicate RNA from the cells without or with incubation with Wnt3 antibody respectively. The fold changes were compared to cells without incubation with Wnt3-antibody. c (right) Western blot was performed with antibody specific against Twist and β-actin was used for loading control. d (left), SKBR3 was pre-treated with LGK974 for 16 h and then treated with TGF-β for additional 24 h. Cell invasiveness was measured by Boyden Chamber Invasion assay as described in “Methods” section. The invasive cells (mean ± SD from five different areas) were counted. *p < 0.05 compared to untreated cells. d (right) The nuclear or cytoplasm expressions of β-catenin were determined by Western blot analysis upon treatment with TGF-β ± LGK974. The α-Tubulin and H3 were used for loading control of cytoplasm and nuclear protein respectively
Fig 4: A83-01 enhanced inhibition activity of trastuzumab on TGF-β-induced cell invasion and migration. a SKBR3 cells were treated with TGF-β, TGF-β plus A83-01, or without any treatment for 4 days and MTT assay was performed at each day as described in “Methods” section. Each data point was six measurements and the graph showed mean of six measurements plus standard deviation, *p < 0.05 and **p < 0.01 compared to untreated cells, ^p < 0.05 and ^^p < 0.01 compared to the TGF-β treatment alone. b SKBR3 cells were incubated with A83-01 for 16 h and then the cells were treated with either TGF-β, trastuzumab, or A83-01 alone or as indicated combination treatment for 24 h. Cell invasiveness was measured by Boyden Chamber Invasion assay as described in “Methods” section. The bars indicated mean number of invaded cells plus stander deviation counted from five different areas, *p < 0.05 compared to untreated cells. c Cell migration was determined by wound healing (Gap Closure) assay. The cells were pre-treated with or without A83-01 for 16 h and then treated with TGF-β ± Trastuzumab. The photos of cell migration were taken after 48 h treatment (top). The bar graph in bottom is quantification of the wound width. The bar indicates the percentage migration rate (wound width compared to untreated control cells) of each condition, and three views were counted, *p < 0.05 compared to the control cells. d Proposed model of the feedback loop between TGF-β and Wnt/β-catenin pathways. TGF-β initiates phosphorylation of Smad3 and nuclear translocation of pSmad3, and then induces Twist binding to E-box at the Wnt3 promoter to regulate Wnt3 during EMT. The upregulated Wnt3 by TGF-β in turn activates Wnt/β-catenin signaling to further upregulated EGFR [18] and Smad pathway. The interaction between the two pathways sustains each other, induces EMT and promotes HER2 cell resistance to therapy. Targeting TGF-βR1 ALK5 kinase could inhibit the TGF-β-initiated pathway interactions and enhance HER2 cell response to trastuzumab treatment
Fig 5: TGF-β-induced EMT and Wnt3 are Smad3 dependent. a SKBR3 cells were treated with TGF-β for 15 min to 24 h. Total protein was extracted at the indicated time points. To measure the phosphorylated TGF-βRI and TGF-βRII, immunoprecipitation was performed by incubating protein lysis with phosphor-Tyrosine antibody first followed by Western blot analysis with antibodies specific to TGFβRI and TGFβRII. The phospho-Smad3 (pSmad3), Twist, E-cadherin, and Wnt3 protein levels were also determined by Western blot analysis. The β-actin was used as loading control. b BT474 and JIMT1 cells were treated with TGF-β from 1 to 24 h and Western blot analysis was performed with the indicated antibodies. c Cells were treated with siSmad3 or negative sequence (Mock) for 48 h. TGF-β was added into the media containing siSmad3 or negative sequence after 24 h siSmad3 treatment. RT-qPCR was performed with Twist (left) and Wnt3 (right) primers. The bars indicate relative expression of the indicated genes adjusted to 18S (mean ± SD from three determinations), *p < 0.01 compared to untreated cells. d In the left panel, BT474 cells were treated with recombinant human Wnt3 protein at the indicated time and total protein was extracted. The pSmad3 was determined by Western blot analysis. The β-actin was used as loading control. In right panel, SKBR3 cells was treated with or without recombinant human Wnt3 protein for 24 h and then cytoplasmic and nuclear fragment was extracted. The pSmad2/3 was determined by Western blot analysis. The α-Tubulin and H3 were used for loading control of cytoplasm and nuclear protein respectively
Supplier Page from OriGene Technologies for Twist (TWIST1) Human shRNA Plasmid Kit (Locus ID 7291)